Nrx pharmaceuticals announces the licensure of a us patent to support use of nrx-101™ for chronic pain

Nrx has licensed us patent 8,653,120 for use of d-cycloserine to treat chronic pain dr. vania apkarian, a world leader in pain and d-cycloserine (dcs) research, has joined the nrx scientific advisory board radnor, pa. , aug. 7, 2023 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company"), a clinical-stage biopharmaceutical company, today announced it has made key advances in developing nrx-101 to treat chronic pain.
NRXP Ratings Summary
NRXP Quant Ranking